Odin, Per
Chaudhuri, K. Ray
Volkmann, Jens
Antonini, Angelo
Storch, Alexander
Dietrichs, Espen
Pirtošek, Zvezdan
Henriksen, Tove
Horne, Malcolm
Devos, David
Bergquist, Filip
Article History
Received: 16 January 2017
Revised: 11 April 2018
Accepted: 12 April 2018
First Online: 10 May 2018
Competing interests
: All participants in the SP meetings received travel expenses and honoraria for their participation in the meetings by Global Kinetic Corporation. P.O. was a study investigator and has received compensations for consultancy and speaker-related activities from Global Kinetic Corporation, AbbVie, Bial, Britannia, Nordic Infucare, UCB, and Zambon. P.O. has received royalties from Uni-Med Verlag. K.R.C. is serving as a journal co-editor-in-chief for <i>npj Parkinson Disease</i>, and was European editor for <i>Basal Ganglia</i>; receives publishing royalties from the following publication: Non-Motor Symptoms of Parkinson’s Disease, Oxford University Press, 2nd edition, 2014 and 1st edition, 2011; has received honoraria from Parkinson’s UK, NIHR, the International Parkinson and Movement Disorder Society, Parkinson’s UK and EU, and UCB, and honoraria for sponsored symposiums from UCB, AbbVie, Britannia, US Worldmeds, Otsuka, Medtronic, Zambon; has served as a consultant for Global Kinetic Corporation, Abbvie, UCB, Britannia, Medtronic and Mundipharma; currently serves on a scientific advisory board for Mundipharma and has served on a scientific advisory board for Eli Lily in April 2013; has received research support from in the form of educational grants from Britannia and UCB, from the National Institute of Health Research (NIHR) (UK and EU, both for development of a non-motor symptoms questionnaire for RLS), and from Parkinson’s UK, and in the form of the following awards: 2016–2018: Horizon 2020 award: i-PROGNOSIS: Intelligent Parkinson eaRly detectiOn Guiding NOvel Supportive InterventionS, 2015–2016: CRN South London contingency funding, and 2014–2016: International Parkinson’s and Movement Disorders Society: Field Validation of the MDS-NMS Scale; and he currently receives license fee payments for the following scales: KPP scale, PDSS-2 scale. Jens Volkmann reports grants and personal fees from Medtronic, personal fees from St. Jude, grants and personal fees from Boston Scientific, personal fees from UCB, personal fees from Merz, personal fees from Allergan, personal fees from TEVA, personal fees from Novartis, personal fees from AbbVie, outside the submitted work; and participation in Global Kinetic Corporation-sponsored advisory boards. A.A. received funding from Neureca foundation, Horizon 2020 Project No 643706 and from Italian National Research, Project No: RF-2009-1530177. He has also received consultancy fees and honoraria for speaker-related activities from AbbVie, Angelini, Acadia, UCB, Zambon, General Electric, Boston Scientific, Medtronic, Mundipharma, and Global Kinetic Corporation. A.S. reports funding from the Deutsche Forschungsgemeinschaft (German Research Association), and the Helmholtz-Association. He has received unrestricted research grants from TEVA Pharma and Global Kinetics Cooperation (Melbourne, Australia), and honoraria for presentations/advisory boards/consultations from Zambon, UCB, Global Kinetic Corporation, AbbVie, Desitin, Mundipharma, Grünenthal, Volkswagen Foundation, Dresden University of Technology, and Lund University, and royalties from Kohlhammer Verlag and Elsevier Press. He serves as an editorial board member of Stem Cells, Stem Cells International, Open Biotechnology Journal and <i>jbc</i> The Journal of Biological Chemistry. E.D. has received honoraria as a consultant from AbbVie, Britannia, and Global Kinetic Corporation, and for lectures from AbbVie, Allergan, Desitin, Global Kinetic Corporation, GSK, Lundbeck, Medtronic, NordicInfu Care, Orion, UCB, and Zambon. Z.P. has received honoraria as a consultant for education-related activities from AbbVie; and participation in Global Kinetic Corporation-sponsored advisory boards. M.H. has a financial interest in Global Kinetic Corporation, is a Director of the Global Kinetic Corporation, and receives consultancy fees from Global Kinetic Corporation. D.D. has received honoraria as a consultant from Global Kinetic Corporation and served on the Scientific Advisory Board for Novartis, Orkyn, Britannia, Apopharma, and Aguettant and has received PHRC grants from the French Ministry of Health and research funding from the ARSLA charity France Parkinson and the European Commission Horizon 2020. He has received various honoraria from pharmaceutical companies for consultancy and lectures on Parkinson’s disease at symposia. F.B. has received honoraria, compensation for lectures and research support in the form of subsidized OM reports from Global Kinetic Corporation. The remaining authors declare no competing interests other than honoraria for their participation in this project from Global Kinetic Corporation.